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Abstract
Ventricular tachycardia (VT) is a common arrhythmia seen in patients with 
heart failure (HF) and is now seen more frequently as these patients survive longer 
with modern therapies. In patients with HF, half of the deaths are sudden due to 
life-threatening ventricular arrhythmias, including VT. Although disease modifying 
drugs, such as beta blockers, mineralocorticoid drugs, and angiotensin receptor 
neprilysin inhibitors, prevent the occurrence of VT to some extent, the mainstay of 
therapy is the antiarrhythmic drug therapy, implantable cardioverter-defibrillator 
(ICD) implantation, and traditional radiofrequency catheter ablation. Autonomic 
nerve system modulation and stereotactic body radiation therapy have emerged 
as novel techniques for the management of refractory VT cases. Patients with 
refractory VT and repetitive ICD shocks should be further evaluated regarding the 
candidacy for left ventricular assist device and transplantation.
Keywords: ventricular tachycardia, heart failure, antiarrhythmic therapy, 
implantable-cardioverter defibrillator, ablation
1. Introduction
Ventricular tachycardia (VT) is common in patients with heart failure (HF). The 
presence and severity of VT increase as the severity of HF increases. Larger infarcts 
with greater left ventricle (LV) systolic dysfunction are more likely to be associated 
with VT. VT forms one of the most common electrical mechanisms responsible 
for sudden cardiac death (SCD) in HF. Patients with LV systolic dysfunction 
who develop VT are at increased risk of SCD from subsequent VT or ventricular  
fibrillation [1].
Patients with VT and HF may present either with cardiac arrest to the emer-
gency department or with palpitations, syncope, chest pain, or ICD shocks to 
cardiology outpatient clinics, varying according to the hemodynamic stability of 
VT. Both non-sustained VT (VT duration < 30 sec) and sustained VT (VT dura-
tion > 30 sec) in patients with HF are associated with significant morbidity and 
mortality. VT storm (three or more separate episodes of sustained VT requiring 
intervention (such as ICD shock or ATP) within 24 hours) is the most troublesome 
condition related with VT and HF.
Although half of the patients with HF have preserved ejection fraction and SCD 
is also a common issue in these patients, there is no proved treatment either by ICD 
or drugs [2]. Because of this, VT and HF will be discussed in the context of HF with 
reduced ejection fraction (HFREF).
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2. Epidemiology
Ventricular tachycardia is common in patients with HF, with up to 20% of 
patients developing VT in 5 years after an ICD was placed [3]. In patients with HF, 
SCD occurs 6–9 times more often than the general population [4]. The most studied 
and proven predictor of ventricular tachyarrhythmia and SCD is left ventricle 
ejection fraction (LVEF) [5]. It has been shown that once the LVEF recovered, the 
incidence of ventricular tachyarrhythmia decreases [6].
The threshold of LVEF <35% represents an accepted threshold at which SCD 
risk is increased and primary prevention is indicated. Several other risk predictors 
of VT, such as non-sustained VT, programmed ventricular stimulation on electro-
physiological study (EPS), microvolt T-wave alternans, late potentials on signal-
averaged electrocardiogram, absence of heart rate variability, QT wave dispersion, 
baroreflex sensitivity, and heart rate turbulence have been proposed for patients 
with HF. However, none of these predictors has influenced the clinical practice.
3. Pathophysiology
There are multiple mechanisms that play a role in the occurrence of VT in 
patients with HF (Table 1). Adverse remodeling and progressive fibrosis occur 
in the ventricle following myocardial infarction (MI) or in association with non-
ischemic cardiomyopathy. These structural alterations as well as the ion channel 
changes form the essential substrate for the induction of VT [7].
The most common mechanism for VT is electrical reentry within and around 
patches of heterogenous myocardial fibrosis, most commonly occurring in areas of 
scar post-myocardial infarction or non-ischemic cardiomyopathy [8]. The scar-
related VT is typically monomorphic with single QRS morphology. Induction of 
monomorphic VT during EPS predicts patients who have the risk of spontaneous 
VT. Polymorphic VT is defined as a continually changing QRS morphology, often 
associated with acute ischemia, drugs which lead to QT prolongation or electrolyte 
imbalance.
Increased sympathetic nervous system (SNS) activation is another trigger for 
induction of VT. SNS activation, via beta-adrenoreceptors activates ryanodine 
receptor on the sarcoplasmic reticulum inside the cardiomyocytes leading to efflux 
of calcium and increase of intracellular concentration which is a trigger for VT. This 
is the rationale under the effect of beta blockers in suppressing VT, as well as SCD in 
HF patients.
Mechanisms
Positive remodeling and fibrosis
Myocardial scar
Electrolyte abnormalities
Increased sympathetic tone
Ischemia
Abnormal calcium handling
Delayed after depolarization
Drugs
Table 1. 
Mechanisms of VT occurrence in patients with heart failure.
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VT occurring within 24–48 hours of acute MI is called primary VT, and acute 
ischemia is considered to be the transient or correctable cause of VT in this case. 
Revascularization is the primary management form of primary VT. VT occurring 
after 48 hours of acute MI is called secondary VT, which is associated with worse 
clinical outcomes.
Increased diastolic calcium levels, early and delayed after depolarizations, and 
some of the drugs also cause VT. Antiarrhythmic drugs are the foremost drugs causing 
VT. Digoxin that is commonly used in the management of HF is an arrhythmogenic 
drug. Dobutamine treatment for acute decompensated HF has also been associated 
with VT [9]. Because of this, patients should be continuously monitorized during 
treatment with dobutamine. VT can also present as a complication of left ventricular 
assist device in an advanced HF patient. Most of these types of VT occur periopera-
tively [10]. It is important to find out the definite mechanism of VT in order to imple-
ment the best effective treatment. In patients with sarcoidosis, for example, VT can 
occur as a result of inflammation, scar or both. If VT is thought to be due to inflamma-
tion, best treatment is antiarrhythmic drug and immunosuppressive, whereas if VT is 
of scar related, best treatment is antiarrhythmic drug and catheter ablation [11].
4. Management
Management of VT in heart failure poses a great challenge to cardiologists since 
antiarrhythmic drugs are limited by incomplete efficacy and unfavorable adverse 
effect profile, ICD is complex and expensive and may affect the quality of life 
adversely because of inappropriate shocks, and invasive catheter ablation owns the 
risk of complication and recurrence. Therefore, multidisciplinary team approach 
including electrophysiologists, heart failure specialists, general cardiologists, inten-
sivists, and cardiovascular surgeon should be used to tackle such a difficult disease.
VT is a life-threatening condition and needs urgent management. Acute man-
agement of VT in HF patients depends on the hemodynamic stability of the patient. 
In hemodynamically unstable VT, the priority is electrical direct current cardio-
version [12]. If the patient is hemodynamically stable, a trial of antiarrhythmic 
treatment should be applied. Intravenous amiodarone is the most effective and safe 
antiarrhythmic treatment in this case [12].
Slow VT (<150 beats/minute) may be tolerated in the short term (Figure 1). 
However, slow VT in the presence of poor ventricular function may cause hemody-
namic compromise in the long term. It is important to closely monitor the patient 
while administering antiarrhythmic therapy. If the antiarrhythmic therapy does 
not cardiovert the patient, shock should be applied as early as possible since sus-
tained VT can compromise hemodynamic status of the patient with left ventricular 
dysfunction in due course. The initial approach to the management of VT should 
include evaluation for correctable causes of VT (e.g., electrolyte abnormalities and 
ischemia). Electrolyte abnormalities, particularly hypokalemia and hypomagnese-
mia which are known to facilitate VT in HF patients should be corrected. Potassium 
and magnesium levels should be kept >4 meq/l and > 2 meq/l, respectively. Agents, 
for example, digoxin, that may induce arrhythmia should be withheld.
For chronic management of VT, optimization of guideline-directed medical 
treatment is very important especially in patients with HFREF. Until recently, 
these treatments consisted of angiotensin converting enzyme inhibitors (ACEis) or 
angiotensin receptor blockers (ARBs), beta blockers (BBs), and mineralocorticoid 
receptor antagonists (MRAs). Of these guideline-directed medical treatments, 
BB and MRA have been proved to prevent sudden cardiac death [13, 14]. These 
drugs have the ability to improve reverse modeling which reduces VT. BBs are the 
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first-line therapy for the management of VT in HF patients. In MADIT-II trial 
(the Multicenter Automatic Defibrillator Implantation Trial II), patients with ICD 
treated with the highest dose of BB experienced less ICD treatment compared to 
patients not taking BB [15].
A meta-analysis compared medical treatment with ICD preventing SCD in 
patients with HF and left ventricular systolic dysfunction. MRAs were found to 
be the most effective drug when added to ACEi and BB, in preventing SCD [16]. 
Zannad et al. also showed that MRAs were equally effective in preventing SCD in 
patients with ICD as without ICD [17].
A newly emerged drug in HFREF, angiotensin receptor neprilysin inhibi-
tor (ARNi), was compared with enalapril in PARADIGM-HF trial (prospective 
comparison of angiotensin neprilysin inhibitor (ARNI) with ACE-i to determine 
impact on global morbidity and mortality in heart failure) [18]. ARNi was shown 
to be superior in reducing cardiovascular death and hospitalization compared to 
enalapril. ARNi also reduced SCD by 20% compared to enalapril. European Society 
of Cardiology 2016 HF guideline has made a class 1 recommendation regarding the 
use of BB, MRA, and ARNi in patients with HFREF and VT [19].
Optimum use of guideline-directed medical treatment prevents development 
of VT to some extent. If the patient continues to be at risk of VT because of low 
ejection fraction, non-sustained or sustained VT, antiarrhythmic drugs, ICD 
implantation, and VT ablation are the subsequent treatment options for chronic 
management of VT. General use of antiarrhythmic drugs in HF is not recommended 
for VT since these drugs, except amiodarone, have been shown to increase mortality 
in patients with HF due to proarrhythmic or negative inotropic effects.
Notorious CAST trial (Cardiac Arrhythmia Suppression Trial) showed that class 
1C agents, encainide, and flecainide increases mortality and non-fatal cardiac arrest 
when used to suppress VT post-myocardial infarction [20]. CAST trial was planned 
to answer the question of whether suppressing ventricular premature beats (VPB) 
also aid in reducing mortality. Patients who had myocardial infarction within the 
preceding 2 years and >6 VPBs on holter recording were enrolled. Those who had MI 
within 90 days were required to have EF < 55%, and those who had MI after this period 
were required to have EF < 40%. Patients were randomly assigned to class1C agents 
(encainide, flecainide, or moricizine). Patients whose PVBs were suppressed were allo-
cated to the treatment with one of the class 1C agent or placebo. The trial was prema-
turely stopped based on the in-term analysis that showed that encainide and flecainide 
used to suppress VPBs increased the mortality by 2.5 times. It is likely that mortality 
excess can be attributed to the proarrhythmic effects of encainide and flecainide.
Figure 1. 
Slow VT at a rate of approximately 125/bpm in a patient on high dose of beta blocker and amiodarone.
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Amiodarone is the sole agent that can be used safely for suppression of VT in HF 
patients. Amiodarone has been studied extensively in patients with left ventricular 
dysfunction. Its efficacy for decreasing mortality in patients with VT and LV dys-
function has not been shown in SCD-HeFT trial (the Sudden Cardiac Death in Heart 
Failure Trial) [21]. However, a meta-analysis including 8522 patients post-myocar-
dial infarction or with systolic HF showed that amiodarone reduced SCD and car-
diovascular mortality [22]. Its safety, unlike class 1 antiarrhythmic agents, has been 
confirmed in this patient population. In patients with more severe HF, amiodarone 
use is associated with adverse prognosis [21]. Amiodarone cannot be used for a long 
period of time because it is associated with multiple side effects, primarily affecting 
thyroid, lung, liver, skin, and eye [23]. Therefore, regular monitoring of lung, liver, 
and thyroid function is required. Due to these side effects, discontinuation rates of 
amiodarone have been noted to be high [22].
Sotalol, a group III antiarrhythmic drug, with BB properties, is highly effective 
in suppressing VT but it is contraindicated in HF patients since increased mortality 
was demonstrated when D-sotalol was used in patients with left ventricular dys-
function after myocardial infarction in SWORD trial [24]. Dofetilide, another class 
III antiarrhythmic drug, failed to reduce arrhythmic death in patients with HF [25]. 
If VT occurs despite amiodarone therapy, mexiletine can be used as an adjunct to 
amiodarone.
Electrophysiologic study was once used for identification of successful antiar-
rhythmic therapy and also the patients who require other advanced therapies. 
Patients were given certain antiarrhythmic drugs after VT was induced at pro-
grammed stimulation. Patients on chronic oral antiarrhythmic drug were then 
assessed whether VT could be induced again [26].
Of the therapies currently available to manage VT, ICD is by far the most 
effective one and has the best supported safety and efficacy data from the trials 
and registries. An ICD has two important components: an ICD generator and a 
lead for sensing, pacing, and shock delivery (Figure 2). ICD improves the survival 
of patients who had VT and syncope, patients who had VT and LVEF<40%, and 
hemodynamic compromise [27]. ICD has been shown to prevent sudden cardiac 
death prophylactically in patents with LVEF <35% resulting both from ischemic or 
non-ischemic cardiomyopathy [21, 28, 29]. The important issue in these primary 
prevention groups is that they should have already received guideline-directed 
medical treatment for at least 3 months before ICD implantation is planned. 
Electrophysiologic study is no longer a required procedure before planning ICD for 
primary prevention.
Figure 2. 
A schematic representation of an intracardiac defibrillator implanted to right ventricle of heart failure patient.
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ICD has antitachycardia pacing (ATP) treatment in addition to defibrillator 
shock and also programs which can discriminate supraventricular tachycardia 
from VT which aids to minimize inappropriate shocks. ATP consists of one or more 
sequence of pacing stimuli, generally expressed as a percentage of tachycardia cycle 
length for a given RR interval. In case of burst ATP, pacing stimuli is delivered at 
constant coupling intervals, whereas ramp ATP consists of pacing stimuli with 
decrement coupling interval (Figure 3). Once VT is confirmed, first therapy in 
the form of ATP was given, and if ATP does not work, then shock is delivered. 
Generally ICD’s VT detection zone is programmed to >167 beats/min and ven-
tricular fibrillation detection zone to >185–200 beats/min. Antiarrhythmic drugs 
commonly prolong VT cycle length and hence cause slow VT, a condition which 
may require to lower the detection zone for VT (Figure 1). In secondary prevention 
patients with HF, the programming of detection zone depends on the cycle length 
of the VT occurred. Generally, the detection zone is programmed 20 bpm slower 
than the rate of the VT occurred before. ATP for faster VT (188–250 bpm) may 
also be programmed with the aim for reducing shocks. ICD shocks are related with 
poor prognosis and quality of life. For this reason, every effort should be made to 
reduce shocks. It was shown that reducing defibrillator shocks was associated with 
increased survival [30].
Cardiac resynchronization therapy (CRT) is also an important milestone in 
the management of moderate to severe HF patients with prolonged QRS dura-
tion (>150 msn and LBBB morphology). CRT without defibrillator (CRT-P) 
can prevent SCD by improving reverse remodeling. CARE-HF Trial (Cardiac 
Resynchronization—Heart Failure) showed that CRT-P prevents SCD by 46% in the 
long term follow-up [31]. Although CRT was shown to reduce new onset VT, it had 
no effect on recurrent VTs [32].
In patients with HF who are refractory to antiarrhythmic therapy, radiofre-
quency catheter ablation has emerged as an important therapeutic option. The 
success rate of this technique varies according to the type of cardiomyopathy. The 
American Heart Association(AHA)/the Heart Rhythm Society (HRS) recommends 
the use of VT ablation in patients with prior myocardial infarction and recurrent 
VT, unresponsive or intolerant to antiarrhythmic treatment [8]. Electrophysiologic 
study (EPS) with programmed electrical stimulation is recommended before abla-
tion in case of sustained monomorphic VT in patients with prior MI [33]. Catheter 
ablation can be effective, but acute complications and long-term VT recurrence risk 
necessitating repeat ablation should be recognized. And worth notifying, procedure 
Figure 3. 
Antitachycardia pacing (ATP) therapy of intracardiac defibrillator. (A) Burst ATP; pacing stimuli at lower 
than VT and constant coupling interval. (B) Ramp ATP; pacing stimuli starting with lower than VT cycle 
length and coupling intervals decreasing at each stimuli.
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of ablation lasts for long hours with extended recovery times. If VT remains refrac-
tory to catheter ablation, repeat ablation may be tried. If the first ablation was done 
by endocardial mapping, repeat ablations may be carried by epicardial mapping. 
Surgical ablation is indicated in patients with VT refractory to antiarrhythmic drugs 
whose catheter ablation has failed [12]. It was shown that surgical cryoablation 
guided by endocardial and epicardial mapping along with aneurysmectomy when 
indicated was a successful way of terminating VT in patients who underwent bypass 
operation [34].
Due to multiple mechanisms of VT in idiopathic dilated cardiomyopathy, the 
success rate of catheter ablation is less than in ischemic cardiomyopathy. It has been 
shown that ablation in this type of cardiomyopathy results in higher recurrence 
rate of VT than ischemic cardiomyopathy [35]. Catheter ablation of VT in dilated 
cardiomyopathy should only be done in patients with clear mechanism of VT (e.g., 
bundle branch reentry) only in experienced centers. Despite these shortcomings, 
successful VT ablation in non-ischemic dilated cardiomyopathy has increased. 
Predictors of recurrence after VT ablation in non-ischemic dilated cardiomyopathy 
were found to be inducibility of sustained VT in the programmed stimulation study, 
poor systolic function (EF < 35%), and delayed intervention time [36].
Worth mentioning, there are some types of VTs occurring in the structurally 
normal heart, termed idiopathic VT. Idiopathic VT is further categorized according 
to the anatomic location in the heart. Most of them originate from the right ventric-
ular outflow tract (RVOT) and have left bundle branch block (LBBB) pattern on the 
electrocardiogram. The second most common idiopathic VT originating from the 
conduction system is termed as fascicular VT. The other idiopathic VT originates 
from the mitral or tricuspid annulus and termed as annular VT. The clinical course 
of idiopathic VT is usually benign; however, if they occur in the form of inces-
sant VT, they may cause LV systolic dysfunction, termed as arrhythmia-induced 
cardiomyopathy (AIC). It is important to differentiate AIC from non-ischemic 
dilated cardiomyopathy because RF ablation is the first line treatment and curative 
in the former [8]. VT originating from left ventricular outflow tract (LVOT) is rare 
compared to VT originating from RVOT. Some form of VTs originating from LVOT 
cannot be ablated by using conventional approach. This unique type of VT with 
LBBB inferior axis and early precordial transition can successfully be ablated from 
the aortic root, using either the left or non-coronary aortic sinus of valsalva [37]. 
VTs can also originate from papillary muscle of left or right ventricle. Ablation of 
papillary muscle VT is difficult compared to other idiopathic VTs. However, there is 
a case report showing successful ablation of incessant VT originating from pos-
terior papillary muscle of right ventricle [38]. EPS is highly recommended before 
ablation of VT in structurally normal hearts which are suspected to be originated 
from RVOT, LVOT, aortic cusps, and epicardial VT [33]. EPS has also a role in case 
of sustained monomorphic VT in patients with arrhythmogenic right ventricular 
dysplasia (ARVD). It was shown that inducibility of sustained monomorphic VT 
during EPS highly predicts SCD, heart transplantation, VT with hemodynamic 
compromise, or syncope in patients with ARVD [39].
Another form of VT occurring in the structurally normal heart is catecholamin-
ergic polymorphic VT. This type of VT should be suspected when syncope trig-
gered by emotion or physical effort occurs in young patients with normal heart and 
QT interval. First line treatment is BBs. Hypertrophic cardiomyopathy (HCM), 
a common cause of SCD in young athletes, is a heterogenous group of cardiomy-
opathy with increased wall thickness. HCM with mid-ventricular obstruction and 
apical aneurysm is a rare form of HCM which is associated with frequent occur-
rence of VT. Prophylactic ICD is the main treatment, but RF ablation is required 
for repetitive VTs [40].
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5. Management of ICD repetitive shocks
Despite ICD can effectively terminate ventricular tachycardia either by anti-
tachycardia pacing or defibrillation shock, it cannot prevent VT recurrences. 
In patients with ICD, prevention of VT recurrence is required to minimize ICD 
shocks which can not only be quite uncomfortable for the patient leading to poor 
quality of life but also cause early battery depletion. Apart from these, recur-
rent shocks lead to HF progression, frequent hospitalization, and mortality. Use 
of antiarrhythmic drugs, particularly amiodarone can reduce ICD appropriate 
shocks by 34% [41]. In the OPTIC study (the Optimal Pharmacological Therapy 
in Cardioverter Defibrillator Patients), beta blocker and amiodarone combina-
tion were shown to be superior in suppression of VT recurrence compared to BB 
alone or sotalol [42]. Drug discontinuation rate at 1 year was found to be 18.2% 
for amiodarone, 23.5% for sotalol, and 5.3% for BB. Mexiletine, a class 1b antiar-
rhythmic drug, was shown to reduce VT recurrence as an adjunct to amiodarone in 
amiodarone-refractory VT in patients with ICD [43]. Ranolazine, a late Na chan-
nel inhibitor, was also shown to reduce VT burden and ICD shocks in patients with 
drug refractory VT and ICD [44].
Radiofrequency catheter ablation can be lifesaving in patients with ICD and 
repetitive shocks. In ischemic cardiomyopathy, some trials such as SMASH-VT 
(Substrate Mapping and Ablation in Sinus Rhythm to Halt Ventricular 
Tachycardia), VTACH (Ventricular Tachycardia Ablation in Coronary Heart 
Disease), and VANISH trials have shown the superiority of ablation for reducing 
ICD shocks [45–47]. The SMASH-VT trial compared ICD implantation plus pro-
phylactic ablation to ICD implantation alone in patients with recent VT. Ablation 
reduced ICD shocks significantly from 31 to 9% and reduced VT from 33 to 12%. 
The VTACH trial assessed the effect of catheter ablation in patients with isch-
emic cardiomyopathy and mappable VT. Ablation significantly prolonged time 
to recurrent VT. The VANISH trial compared catheter ablation to escalation of 
antiarrhythmic therapy on top of first-line antiarrhythmic therapy in patients 
with VT. Ablation significantly reduced composite outcome of death, appropriate 
ICD shocks, and VT storm. Repetitive ICD shocks should also warrant referral to 
an advanced heart failure unit, capable for left ventricular assist device (LVAD) 
implantation and transplantation [48]. Catheter ablation of VT has risk of compli-
cation like all other invasive procedures. Complications related to these procedures 
are cardiac perforation, systemic embolism including myocardial infarction/stroke, 
vascular complications, and mortality.
Autonomic modulation procedures may also be applied for VT refractory to 
ablation. It was shown that videoscopic surgical cardiac sympathetic denervation 
may reduce the number of ICD shocks in refractory cases [49]. The surgery involves 
removal of the lower half of the stellate ganglion and T2-T4 stellate ganglia. This 
technique is especially effective when sympathetic denervation was made bilater-
ally. Renal denervation was also shown to reduce VT recurrences [50].
Stereotactic body radiation therapy (SBRT) for VT in HF patients has recently 
emerged as a new way of suppression of VT. SBRT is a technique that delivers 
high dose of radiation (25 gray) to target tissues with reduced exposure to normal 
adjacent tissues. SBRT has been used for decades to target various cancers. First, 
Cuculich et al. showed a 99.9% reduction in VT burden with cardiac SBRT in a 
case series of five patients with a high burden of drug-refractory VT, who had 
been suffering through repeated ICD shocks [51]. And recently, ENCORE VT trial 
showed that SBRT reduced VT and premature ventricular contraction episodes 94% 
at 6 months among 18 patients with treatment refractory VT, over half of whom 
presented with VT storm [52].
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In selected cases with recurrent VT which cannot be managed with the treat-
ment recommendation given above, implantation of LVAD could temporarily 
stabilize patient hemodynamically, as well as improve reverse remodeling. LVAD 
is a battery-operated mechanical pump, which takes the blood from failed LV and 
pumps it to the aorta to be transmitted to the rest of the body (Figure 4). There are 
not many heart failure patients with LVAD. However, the management of VT in this 
patient population requires mention since it is somewhat different than HF patients 
without LVAD. LVAD may be able to continue maintaining cardiac output in spite of 
sustained VT, and most of the LVAD patients have ICD in place. When such patients 
present to the emergency department, first patient hemodynamic status should be 
assessed. If the blood pressure checked by Doppler ultrasonography is okay, it is 
reasonable to transfer the patient to a tertiary center where there is LVAD specialist 
and electrophysiologist. If there is hemodynamic compromise, then the patient 
should be immediately converted to normal sinus rhythm with electrical shock [53]. 
If the patient is a candidate neither for transplantation nor LVAD, end-of-life care 
should be applied for palliation. Shared decision making with the patient and rela-
tives should be done, and discussion regarding measures such as ICD deactivation 
may be applied in these patients.
Figure 4. 
A schematic representation of a left ventricle assist device (LVAD) showing battery-operated mechanical pump 
taking blood from left ventricle and pumping it to aorta.
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VT storm is a medical emergency requiring prompt intervention. Reversible 
causes of VT, such as hypokalemia, hypomagnesemia, ischemia, and hypoxia 
should be sought and corrected where applicable. Beta blocker dose should be 
uptitrated to decrease the sympathetic tone. Another intervention to reduce sym-
pathetic drive is sedation. Radiofrequency catheter ablation has been shown to be 
effective in controlling VT storm [54].
6. Conclusion
Ventricular tachycardia is a frequent event in HF population and is one of the 
poor prognostic factors related with HF. Management of VT is important because 
it is associated with SCD which is the responsible cause of death in 50% of patients 
with HF. Optimization of guideline-directed treatment is the most important step 
to prevent occurrence of VT in these patients. ICD has resulted marked improve-
ment in survival of patients with HF and VT. However, repetitive ICD shocks due 
to recurrent VT poses a great problem and decreases survival. Antiarrhythmic 
therapy and VT ablation generally offer a complementary treatment in patients with 
ICD. Patients with VT who have failed standard therapy (antiarrhythmic therapy 
and catheter ablation) have limited options, with one-year survival below 20%. 
Autonomic modulation procedures and stereotactic body radiation therapy could be 
applied in patients with refractory VT. Patients with recurrent VT despite all other 
measures should be referred to tertiary centers where they are evaluated in respect 
of indications for LVAD implantation and transplantation.
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